| Dr Paul Allen Rosenblatt, MD | |
|
4220 Harding Road, Rudy Cancer Center, Nashville, TN 37205-2005 | |
| (615) 222-6755 | |
| (615) 222-3567 |
| Full Name | Dr Paul Allen Rosenblatt |
|---|---|
| Gender | Male |
| Speciality | Radiation Oncology |
| Experience | 47 Years |
| Location | 4220 Harding Road, Nashville, Tennessee |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003905969 | NPI | - | NPPES |
| 3196796 | Medicaid | TN | |
| 3079627 | Other | TN | BC/BS OF TENNESSEE |
| 64720105 | Medicaid | KY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0203X | Radiology - Therapeutic Radiology | MD0000011643 (Tennessee) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Tennessee Oncology, Pllc | 4688586134 | 223 |
News Archive
Nuvo Research Inc., a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today announced the results of its 16-week, double-blind, placebo-controlled, Phase 2 clinical trial conducted in Germany to compare the safety and efficacy of WF10 and its main constituents (sodium chlorite and sodium chlorate) with saline in patients with refractory allergic rhinitis and to compare the safety and efficacy of WF10 and its main constituents.
In the study published today in the Journal of Clinical Investigation (JCI), one of the journals with highest impact in experimental medicine, the researchers associate the activity of the DOR protein with muscle atrophy and point to DOR as a plausible target against which to develop a drug to prevent muscle deterioration in certain diseases.
Scientists have made a discovery that could lead to improved treatment for asthma sufferers.They have found that blocking a certain signalling molecule can alleviate symptoms such as mucus production, swelling (edema), and constriction of the airways in the lungs.
University of Pittsburgh Cancer Institute (UPCI) researchers have identified over 125 genetic components in a chemotherapy-resistant, brain tumor-derived cell line, which could offer new hope for drug treatment to destroy the cancer cells.
As the debate surrounding the Affordable Care Act (ACA) looms in the U.S. Congress, Johns Hopkins researchers are weighing in on one aspect of the law. In 2014, as part of the ACA, Maryland was one of the states that expanded eligibility for its Medicaid program.
› Verified 2 days ago
| Entity Name | Tennessee Oncology, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811955917 PECOS PAC ID: 4688586134 Enrollment ID: O20031103000534 |
News Archive
Nuvo Research Inc., a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today announced the results of its 16-week, double-blind, placebo-controlled, Phase 2 clinical trial conducted in Germany to compare the safety and efficacy of WF10 and its main constituents (sodium chlorite and sodium chlorate) with saline in patients with refractory allergic rhinitis and to compare the safety and efficacy of WF10 and its main constituents.
In the study published today in the Journal of Clinical Investigation (JCI), one of the journals with highest impact in experimental medicine, the researchers associate the activity of the DOR protein with muscle atrophy and point to DOR as a plausible target against which to develop a drug to prevent muscle deterioration in certain diseases.
Scientists have made a discovery that could lead to improved treatment for asthma sufferers.They have found that blocking a certain signalling molecule can alleviate symptoms such as mucus production, swelling (edema), and constriction of the airways in the lungs.
University of Pittsburgh Cancer Institute (UPCI) researchers have identified over 125 genetic components in a chemotherapy-resistant, brain tumor-derived cell line, which could offer new hope for drug treatment to destroy the cancer cells.
As the debate surrounding the Affordable Care Act (ACA) looms in the U.S. Congress, Johns Hopkins researchers are weighing in on one aspect of the law. In 2014, as part of the ACA, Maryland was one of the states that expanded eligibility for its Medicaid program.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Paul Allen Rosenblatt, MD Po Box 440261, Nashville, TN 37244-0261 Ph: (615) 329-0570 | Dr Paul Allen Rosenblatt, MD 4220 Harding Road, Rudy Cancer Center, Nashville, TN 37205-2005 Ph: (615) 222-6755 |
News Archive
Nuvo Research Inc., a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today announced the results of its 16-week, double-blind, placebo-controlled, Phase 2 clinical trial conducted in Germany to compare the safety and efficacy of WF10 and its main constituents (sodium chlorite and sodium chlorate) with saline in patients with refractory allergic rhinitis and to compare the safety and efficacy of WF10 and its main constituents.
In the study published today in the Journal of Clinical Investigation (JCI), one of the journals with highest impact in experimental medicine, the researchers associate the activity of the DOR protein with muscle atrophy and point to DOR as a plausible target against which to develop a drug to prevent muscle deterioration in certain diseases.
Scientists have made a discovery that could lead to improved treatment for asthma sufferers.They have found that blocking a certain signalling molecule can alleviate symptoms such as mucus production, swelling (edema), and constriction of the airways in the lungs.
University of Pittsburgh Cancer Institute (UPCI) researchers have identified over 125 genetic components in a chemotherapy-resistant, brain tumor-derived cell line, which could offer new hope for drug treatment to destroy the cancer cells.
As the debate surrounding the Affordable Care Act (ACA) looms in the U.S. Congress, Johns Hopkins researchers are weighing in on one aspect of the law. In 2014, as part of the ACA, Maryland was one of the states that expanded eligibility for its Medicaid program.
› Verified 2 days ago
Arthur Fleischer, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 3601 Tvc, Nashville, TN 37232 Phone: 615-322-3000 | |
Dr. Cari L Motuzas, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1161 21st Ave S, Ccc-1121 Med Ctr N, Department Of Radiology, Nashville, TN 37232 Phone: 615-322-3780 | |
John O Nunes, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 210 25th Ave N Ste 1204, Nashville, TN 37203 Phone: 615-312-0600 | |
Dr. Christopher C Ng, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 210 25th Ave N Ste 1204, Nashville, TN 37203 Phone: 615-312-0600 | |
Jennifer Leslie Robinson Williams, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 3601 The Vanderbilt Clinic, Nashville, TN 37232 Phone: 615-322-3000 | |
Dr. Robert J Stallworth, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 210 25th Ave N Ste 602, Nashville, TN 37203 Phone: 615-312-0600 Fax: 615-320-3259 |